Bioventus (BVS)
NASDAQ:BVS
Want to see BVS full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.22Last Year’s EPS
0.21Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong financial momentum: solid revenue growth (+7%), robust adjusted EBITDA expansion (+24%), improved margins and materially stronger cash flow (+$28M YoY), along with raised EPS and cash guidance. Management is accelerating targeted investments (primarily into PNS, PRP, Ultrasonics and International) and added senior leadership to scale new businesses. Offsetting items include a one-time favorable rebate that boosted Q1 results, near-term margin volatility as investments ramp, early-stage nature of new growth drivers, distributor inventory/timing headwinds in Pain, and a still-material debt balance ($272M) that remains a focus. Overall, the positives (growth, profitability, cash generation and proactive reinvestment) outweigh the manageable near-term challenges.Company Guidance
Revenue Growth and Guidance Reaffirmed
Q1 revenue of $132.0M, up 7% year-over-year; company reaffirmed 2026 revenue guidance at $600M–$610M.
Strong Adjusted EBITDA Expansion
Adjusted EBITDA of $24M, up 24% YoY (~$5M increase); adjusted EBITDA margin expanded to 18%, up 260 basis points versus prior year.
Adjusted EPS Nearly Doubled and Guidance Raised
Adjusted EPS of $0.15 in Q1 vs $0.08 prior year (nearly double); full-year adjusted EPS guidance increased to $0.75–$0.79 (up $0.02).
Improved Gross Margin and Profitability
Adjusted gross margin 76%, up 110 basis points YoY driven by a favorable rebate adjustment and a refund of prior-year tariffs; adjusted operating income $20M (up ~ $3M) and adjusted net income $13M (up $7M).
Material Cash Flow and Balance Sheet Progress
Cash from operations was $9M in Q1, an increase of ~$28M YoY and the largest Q1 operating cash flow since becoming public; cash on hand $36M and debt reduced by $22M to $272M; company expects net leverage <2x by end of Q2 2026.
International and Segment Momentum
International revenue grew 17% YoY (11% constant currency); Pain Treatments +8%, Surgical +6% and Restorative Therapies +5%; Ultrasonics showed improved growth in Europe and is positioned to be a growth driver.
Focused Investment in Growth Drivers and Leadership Hire
Company is accelerating investment into PNS, PRP, Ultrasonics and International (planned $13M incremental investment for the year, with >50% of planned investments targeted at PNS); hired Megan Rosengarten as General Manager for PNS to scale the business.
Upgraded Cash From Operations Guidance
Full-year cash from operations guidance raised to $84M–$89M (up $2M versus prior guidance).
BVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BVS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $10.68 | $10.92 | +2.25% |
Mar 05, 2026 | $8.47 | $9.10 | +7.44% |
Nov 04, 2025 | $6.56 | $7.55 | +15.09% |
Aug 06, 2025 | $6.14 | $7.29 | +18.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bioventus (BVS) report earnings?
Bioventus (BVS) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Bioventus (BVS) earnings time?
Bioventus (BVS) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BVS EPS forecast?
BVS EPS forecast for the fiscal quarter 2026 (Q2) is 0.22.